A specific form of vitamin E improved the most severe form of fatty liver disease in some children, according to a study funded by the National Institutes of Health. Results appear in the April 27 issue of the Journal of the American Medical Association. A previous study found vitamin E effective in some adults with the disease.
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease among U.S. children. NAFLD ranges in severity from steatosis (fat in the liver without injury) to nonalcoholic steatohepatitis or NASH (fat, inflammation, and liver damage). Fatty liver increases a child’s risk of developing heart disease and liver cirrhosis. The only way to distinguish NASH from other forms of fatty liver disease is with a liver biopsy. Weight loss may reverse the disease in some children, but other than dietary advice, there are no specific treatments. Excess fat in the liver is believed to cause injury by increasing levels of oxidants, compounds that damage cells.
Most children with fatty liver disease are overweight and resistant to insulin, a critical hormone that regulates energy. Boys are more likely affected than girls, as are Hispanic children compared to African-Americans and whites.
Using liver biopsies, researchers found that after 96 weeks of treatment, 58 percent of the children on vitamin E no longer had NASH, compared to 41 percent of the children on metformin (a diabetes drug), and 28 percent on placebo. Vitamin E was better than placebo because it significantly reduced enlargement and death of liver cells.
"These results suggest that vitamin E improves or resolves NASH in at least half of children, which we previously showed to be true in adults," said Stephen P. James, M.D., director of the digestive diseases and nutrition division at NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which funded the study. While the results are encouraging, patients using vitamin E for NASH should be under a doctor’s care. "We hope to build on these results by looking for other therapies and reliable, non-invasive ways to monitor the disease and response to therapy."
The Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) trial studied whether vitamin E (an antioxidant) or metformin could improve fatty liver disease. The endpoint to measure success was either a sustained reduction in the liver enzyme alanine aminotransferase (ALT) or improvements in the liver as shown by biopsies. A total of 173 children, mostly whites and Hispanics ages 8 to 17, were recruited into three treatment groups. The children received either 500 milligrams of metformin or 400 international units of a natural form of vitamin E or placebo twice a day for two years.
Neither vitamin E nor metformin were significantly better than placebo in reducing ALT levels. Twenty-six percent of patients on vitamin E, 16 percent on metformin, and 17 percent of those on placebo had reduced liver enzyme levels. Interestingly, ALT levels improved more rapidly among patients on vitamin E (within six months) compared to those on placebo. The ALT levels among the children on placebo improved over the two years.
"We believe all children in the trial benefited from the frequent diet and exercise advice provided throughout the study," said Joel E. Lavine, M.D., Ph.D., a TONIC principal investigator and professor of pediatrics at Columbia University, New York. "Now we have information on the natural history of a placebo group over time, which will help us design future trials."
Using biopsies in children with liver disease is unique. "TONIC is ground-breaking on two fronts. It is the first study to use liver biopsy to evaluate potential treatments for any liver disease in children," said Patricia Robuck, Ph.D., M.P.H., the project scientist at NIDDK. "It is also the first multi-center, randomized, controlled trial to use a liver biopsy to evaluate a therapy for fatty liver in children, considered the most rigorous design for studies of liver disease."
TONIC was conducted by NASH Clinical Research Network investigators at:Case Western Reserve University and the Cleveland Clinic, Cleveland
Additional NIH support for TONIC was provided by the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Center for Research Resources. Learn more about TONIC at www.clinicaltrials.gov (search for NCT00063635) and about the NASH network at http://www.jhucct.com/nash/open/centers/centers.htm.
The NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition and obesity; and kidney, urologic and hematologic diseases. Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe and disabling conditions affecting Americans. For more information about the NIDDK and its programs, see www.niddk.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
Leslie Curtis | EurekAlert!
A whole-body approach to understanding chemosensory cells
13.12.2017 | Tokyo Institute of Technology
Research reveals how diabetes in pregnancy affects baby's heart
13.12.2017 | University of California - Los Angeles Health Sciences
MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.
Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...
Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...
Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.
To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...
The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.
Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...
With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong
Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
13.12.2017 | Health and Medicine
13.12.2017 | Physics and Astronomy
13.12.2017 | Life Sciences